Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT market SEOUL, South Korea, Nov. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics...

Lunit: Six posters featuring the Lunit SCOPE suite and new insights into the tumor microenvironment are to be showcased at the SITC 2023 Annual Meeting SEOUL, South Korea, Nov. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading...

Lunit: Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading...

Lunit 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SCOPE across diverse cancer types at SITC 2023 SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of...

Lunit, a firm specializing in cancer diagnostics and therapeutics powered by artificial intelligence (AI), announced the presentation of data from a collaborative study on the use of the Lunit SCOPE IO test to predict immunotherapy treatment...

Lunit: Collaborative study with NCCHE shows that AI analysis of HER2 expression and the tumor microenvironment is linked to treatment response of Pertuzumab+Trastuzumab in colorectal cancer [SEOUL, South Korea, August 1, 2023] Lunit...